Senior Research Scientist @ Flatiron Health, providing real world evidence for clinical decision making nationwide.
Research Affiliate @ UPENN (genomics of mBC)
@AlbertGrinshpun@CD_AACR@CancerDiscovery It is! Still working on the fancy formatted version with embedded figures, but the provided PDF has been fully peer reviewed. Let me know if you'd like help navigating!
@liambrownmn@ElizSMcKenna@CD_AACR@AngieDemichele@Penn_CBIO@PennCancer@PennMedicine i) Clinical decisions should consider new driver mutations acquired in mets (longitudinal sequencing is a must).
ii) Mutation recurrence occurs at the pathway-level, we should consider the larger picture beyond limited gene panels
iii) DTCs evolve overtime
Are new mutations really necessary for metastasis?
The role of genetic evolution in metastasis remains hotly debated. Our new Cancer Discovery paper provides evidence that mutations acquired during clinical latency are critical for metastatic outgrowth in breast cancer.
New publication: "Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination". See other thread for more details. #BreastCancer#Genomics@Penn_CBIO https://t.co/ZwrVdurRAF
These results provide further evidence that newly detected mutations in breast cancer metastases were indeed acquired after dissemination and are bona fide drivers of metastasis. As such, metastasis results from clinically relevant evolution and should be treated as such.
My new work in the Chodosh Lab provides evidence that breast cancer metastases result from the acquisition of new driver mutations after dissemination from the primary tumor, and thus should be treated as a distinct entities : https://t.co/mAW8aNvpUQ. #BreastCancer#Genomics
We also present a probabilistic framework that suggested that it is exceedingly unlikely that putative metastatic driver mutations were sequentially acquired in a rare subclone of the primary tumor without non-random and significant clonal expansion
I was honored to have been able to contribute a small % to the gargantuan effort by Amulya Sreekumar in the Chodosh Lab to elucidate the role of heparan sulfate-mediated FGF signaling in breast cancer dormancy https://t.co/mbgXnwUYKy
Online Now: B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling https://t.co/WnuTE7dFYu
In 2020, I implicated PAQR8 gain in metastases based solely on genomic assays. Since then, Saisai Chen just published her work in our lab which extensively shows that PAQR8 gain promotes breast cancer recurrence and treatment resistance. I'm ecstatic!
https://t.co/O4pCWiejqT
Super excited to share my article w/ Justin Humphreys @VU_Philosophy arguing for an explanatory parallel b/w Working Memory & the Aristotelian faculty of phantasia! 6 years in the making & finally in print (open access) near you! smol 🧵 below
https://t.co/iPxw25hqj7